These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 16528141

  • 1. Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
    Papadimitriou GN, Theleritis CG, Dikeos DG, Psarros CJ, Soldatos CR.
    Int Clin Psychopharmacol; 2006 May; 21(3):181-4. PubMed ID: 16528141
    [Abstract] [Full Text] [Related]

  • 2. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
    Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF.
    Neuroendocrinology; 2007 May; 85(4):249-56. PubMed ID: 17570902
    [Abstract] [Full Text] [Related]

  • 3. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ, Regenbogen B, Sachse J, Eich FX, Härtter S, Hiemke C.
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [Abstract] [Full Text] [Related]

  • 4. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.
    Lin CC, Bai YM, Wang YC, Chen TT, Lai IC, Chen JY, Chen SY, Gau SS, Liou YJ.
    J Clin Psychopharmacol; 2009 Dec; 29(6):529-36. PubMed ID: 19910716
    [Abstract] [Full Text] [Related]

  • 5. THE LESSA (Lebanese Short-term Study with Amisulpride) STUDY a Phase IV clinical trial in acutely ill schizophrenic patients.
    Baddoura R, Ourgandjian H.
    J Med Liban; 2004 Dec; 52(2):78-85. PubMed ID: 15884686
    [Abstract] [Full Text] [Related]

  • 6. Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.
    Rettenbacher MA, Hummer M, Hofer A, Baumgartner S, Ebenbichler C, Edlinger M, Kemmler G, Lechleitner M, Wolfgang Fleischhacker W.
    J Psychopharmacol; 2007 Jun; 21(4):400-4. PubMed ID: 17050656
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S, Patel A, Kerwin RW, Knapp M, Travis MJ.
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [Abstract] [Full Text] [Related]

  • 9. Effects of second generation antipsychotics on leptin and ghrelin.
    Esen-Danaci A, Sarandöl A, Taneli F, Yurtsever F, Ozlen N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug 01; 32(6):1434-8. PubMed ID: 18579280
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
    Mann K, Bartels M, Bauer H, Gaertner HJ.
    Pharmacopsychiatry; 1984 Jul 01; 17(4):111-5. PubMed ID: 6147865
    [Abstract] [Full Text] [Related]

  • 13. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
    Molina JD, Lerma-Carrillo I, Leonor M, Pascual F, Blasco-Fontecilla H, González-Parra S, López-Muñoz F, Alamo C.
    Clin Neuropharmacol; 2009 Jul 01; 32(1):10-5. PubMed ID: 18978498
    [Abstract] [Full Text] [Related]

  • 14. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
    Cook B, Hoogenboom G.
    Australas Psychiatry; 2004 Mar 01; 12(1):74-6. PubMed ID: 15715745
    [Abstract] [Full Text] [Related]

  • 15. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
    Kim EY, Kim SH, Lee NY, Jung DC, Kim YS, Ahn YM.
    Pharmacopsychiatry; 2012 Mar 01; 45(2):57-63. PubMed ID: 22411694
    [Abstract] [Full Text] [Related]

  • 16. How do we choose between atypical antipsychotics? The advantages of amisulpride.
    Mortimer AM.
    Int J Neuropsychopharmacol; 2004 Mar 01; 7 Suppl 1():S21-5. PubMed ID: 14972081
    [Abstract] [Full Text] [Related]

  • 17. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.
    Ahn YM, Lee KY, Kim CE, Kim JJ, Kang DY, Jun TY, Choi JS, Chung IW, Kim SH, Hwang SS, Kim YS.
    J Clin Psychopharmacol; 2009 Apr 01; 29(2):117-23. PubMed ID: 19512972
    [Abstract] [Full Text] [Related]

  • 18. Weight change with atypical antipsychotics in the treatment of schizophrenia.
    Haddad P.
    J Psychopharmacol; 2005 Nov 01; 19(6 Suppl):16-27. PubMed ID: 16280334
    [Abstract] [Full Text] [Related]

  • 19. Amisulpride related tic-like symptoms in an adolescent schizophrenic.
    Lin CL, Shiah IS, Yeh CB, Wan FJ, Wang TS.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan 01; 30(1):144-6. PubMed ID: 16225977
    [Abstract] [Full Text] [Related]

  • 20. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study.
    Hrdlicka M, Zedkova I, Blatny M, Urbanek T.
    Neuro Endocrinol Lett; 2009 Jan 01; 30(2):256-61. PubMed ID: 19675512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.